scorecardresearch
Follow Us:
Saturday, June 19, 2021

DRL would infringe on Lunesta patent: US court

The United States Court of Appeals for the Federal Circuit has ruled that Dr Reddy’s Laboratories Ltd (DRL) would infringe on the patent of Sunovion Pharmaceuticals blockbuster drug Lunesta.

Written by Press Trust Of India | Hyderabad |
September 28, 2013 4:05:04 am

The United States Court of Appeals for the Federal Circuit has ruled that Dr Reddy’s Laboratories Ltd (DRL) would infringe on the patent of Sunovion Pharmaceuticals blockbuster drug Lunesta.

The court delivered its verdict on Thursday.

Setting aside an earlier ruling given by a New Jersey Court,the Federal Circuit Court said that the lower court has “erred” in granting summary judgement of non-infringement by Dr Reddy’s (DRL). Lunesta (eszopiclone) is the prescription brand to treat insomnia.

Sunovin is a wholly-owned subsidiary of Dainippon Sumitomo Pharma Co. Ltd (DSP).

According to Dainippon Sumitomo Pharma,Lunesta generated $136 million revenues in North America and Chinese markets in the April-June quarter of the current financial year.

“In view of the foregoing,we conclude that the district court’s construction of the asserted claims was correct,but we also conclude that the court erred in granting summary judgement of non-infringement to Reddy. Therefore,because Reddy’s ANDA (Abbreviated New Drug Application) specification infringes claim 1 of Sunovion’s 673 patent as a matter of law,the judgement of the district court is reversed,” the court said in its order.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest News Archive News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
Advertisement
Advertisement
Advertisement
Advertisement